GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (FRA:IQI) » Definitions » EV-to-Revenue

Incannex Healthcare (FRA:IQI) EV-to-Revenue : (As of May. 21, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Incannex Healthcare EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Incannex Healthcare's enterprise value is €19.65 Mil. Incannex Healthcare's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Incannex Healthcare's EV-to-Revenue for today is .

The historical rank and industry rank for Incannex Healthcare's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Incannex Healthcare was 350.20. The lowest was 4.92. And the median was 76.57.

FRA:IQI's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.42
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), Incannex Healthcare's stock price is €0.0175. Incannex Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Incannex Healthcare's PS Ratio for today is .


Incannex Healthcare EV-to-Revenue Historical Data

The historical data trend for Incannex Healthcare's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare EV-to-Revenue Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.82 16.16 38.68 123.33 -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Incannex Healthcare's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's EV-to-Revenue falls into.



Incannex Healthcare EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Incannex Healthcare's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=19.650/0
=

Incannex Healthcare's current Enterprise Value is €19.65 Mil.
Incannex Healthcare's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare  (FRA:IQI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Incannex Healthcare's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0175/0
=

Incannex Healthcare's share price for today is €0.0175.
Incannex Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (FRA:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.